Article
Multidisciplinary Sciences
Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue
Summary: Antiviral therapy for chronic hepatitis C reduces the risk of hepatocellular carcinoma (HCC) occurrence in Japanese patients.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Chiara Rocha, Erin H. Doyle, Chip A. Bowman, M-Isabel Fiel, Ashley E. Stueck, Nicolas Goossens, Kian Bichoupan, James F. Crismale, Jasnit Makkar, Sara Lewis, Ponni V. Perumalswami, Thomas D. Schiano, Yujin Hoshida, Myron Schwartz, Andrea D. Branch, Neal Patel
Summary: Successful treatment of hepatitis C reduces liver inflammation and fibrosis, but patients are still at risk of developing hepatocellular carcinoma. Risk factors for post-SVR HCC include non-Caucasian race, smoking, age over 60, low albumin level, elevated AST/ALT ratio, and low platelet count. AFP may be a promising marker for post-SVR HCC risk.
Article
Medicine, General & Internal
In Jung Kim, Sung Hwan Yoo, Sora Kim, Young Youn Cho, Ki Young Yoo, Hyung Joon Kim, Hyun Woong Lee
Summary: In patients with chronic hepatitis C and hemophilia, treatment with PegIFN/RBV resulted in stable SVR and a low incidence of HCC. Although the follow-up period was short, DAAs were found to lead to more stable SVR than PegIFN/RBV and a low incidence of HCC.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Immunology
Oscar C. Araujo, Vanessa S. de Paula, Kycia M. do O, Cristiane A. Villela-Nogueira, Natalia M. Araujo
Summary: The study revealed that GSTT1 gene polymorphisms have different distributions at different stages (chronic hepatitis, cirrhosis, and hepatocellular carcinoma) of HCV infection, which may impact liver disease progression. However, the distribution of GSTM1 gene polymorphisms or combined GSTM1/GSTT1 double-null genotypes did not significantly vary between the stages.
Article
Immunology
Jie Li, Hwai- Yang, Ming-Lun Yeh, Michael H. Le, An K. Le, Yee Hui Yeo, Chia-Yen Dai, Scott Barnett, Jian Q. Zhang, Jee-Fu Huang, Huy N. Trinh, Christopher Wong, Clifford Wong, Joseph K. Hoang, Ramsey Cheung, Ming-Lung Yu, Mindie H. Nguyen
Summary: This study found that concurrent FL in patients with CHB significantly reduces the risk of cirrhosis and HCC, as well as increases the rate of HBsAg seroclearance. Further research is needed to confirm these findings and investigate the underlying mechanisms of FL on CHB.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Immunology
Christine C. Hsu, Harish Gopalakrishna, Maria Mironova, Mei-Hsuan Lee, Chien-Jen Chen, Hwai- Yang, Manfred Wiese, Kyong-Mi Chang, Elizabeth C. Wright, Tomilowo Abijo, Jordan J. Feld, David E. Kaplan
Summary: In a hepatitis C virus (HCV)-controlled human infection model (CHIM), researchers assessed the risk of hepatocellular carcinoma (HCC) after viral clearance in noncirrhosis patients with sustained virological response (SVR) to HCV treatment. The overall HCC rate in noncirrhosis SVR patients was 0.33 per 100 patient-years. The data suggests that the risk of HCC in the HCV CHIM is very low or negligible.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Gastroenterology & Hepatology
Won-Mook Choi, Gi-Ae Kim, Jonggi Choi, Gwang Hyeon Choi, Yun Bin Lee, Dong Hyun Sinn, Young-Suk Lim
Summary: This study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in patients with CHB without cirrhosis. The study found that patients with moderate baseline viral load had the highest HCC risk.
Article
Oncology
Cortlandt M. Sellers, Johannes Uhlig, Johannes M. Ludwig, Jeffrey S. Pollak, Tamar H. Taddei, Stacey M. Stein, Joseph K. Lim, Hyun S. Kim
Summary: Inflammation and the immune system play a significant role in the prognosis of hepatocellular carcinoma in Western patients with chronic viral hepatitis, with the neutrophil-to-lymphocyte ratio (NLR) potentially serving as a prognostic biomarker.
Article
Oncology
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A. Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Summary: The study found a significant association between physical activity and development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with potent antiviral therapy, with increasing physical activity being beneficial in reducing the risk of HCC development.
Review
Biochemistry & Molecular Biology
Nicholas Noverati, Rukaiya Bashir-Hamidu, Dina Halegoua-DeMarzio, Hie-Won Hann
Summary: Hepatitis B virus is a significant cause of hepatocellular carcinoma globally. The complex mechanisms of this virus include interactions with the host's immune system. Factors such as stress can amplify these mechanisms. Chronic stress, harmful to health, can suppress or activate the host's defense system, leading to tumor initiation and progression in liver cancer. Chronic stress, often overlooked, should be recognized as a potential risk factor.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Francesco Paolo Russo, Alberto Zanetto, Elisa Pinto, Sara Battistella, Barbara Penzo, Patrizia Burra, Fabio Farinati
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death, with chronic viral hepatitis being a significant contributing factor. The pathophysiology of viral-related HCC involves liver inflammation, oxidative stress, and deregulation of cell signaling pathways. Regular ultrasound surveillance is recommended for patients with cirrhosis and high-risk individuals with chronic HBV infection. Antiviral therapy reduces the risks of HCC development and recurrence. Various scoring systems have been developed to predict the risk of HCC development in patients with chronic hepatitis B.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Hou-Ying Cheng, Rey-Heng Hu, Chih-Yang Hsiao, Ming-Chih Ho, Yao-Ming Wu, Po-Huang Lee, Cheng-Maw Ho
Summary: This study aimed to investigate the survival outcomes of antiviral agents in patients with hepatitis C virus who underwent liver resection for primary hepatocellular carcinoma. The results showed that antiviral treatment can prolong overall survival, and DAAs may have a protective effect against hepatic decompensation.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Rania M. Bondok, Lamiaa A. Barakat, Alyaa R. Elsergany, Nancy Mahsoub, Maivel H. Ghattas
Summary: The overexpression of IFITM3 in hepatocellular carcinoma Egyptian patients was investigated in this study. The results showed that IFITM3 rs 12252-CC was significantly elevated in HCC patients compared to the control group with HCV infection.
Review
Biochemistry & Molecular Biology
Phumelele Yvonne Siphepho, Yi-Ting Liu, Ciniso Sylvester Shabangu, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Ming-Lung Yu, Shu-Chi Wang
Summary: Metabolic derangement, particularly steatosis, is common in HCV-infected patients and may independently affect treatment outcomes. Genotype 3 HCV-infected patients have higher prevalence and severity of steatosis compared to other genotypes.
Article
Medicine, General & Internal
Jian Wang, Weimao Ding, Jiacheng Liu, Yong Liu, Xiaomin Yan, Juan Xia, Weihua Wu, Bei Jia, Yuxin Chen, Dongmei Gao, Shuqin Hong, Xiaohong Wang, Li Wang, Xin Tong, Shengxia Yin, Zhaoping Zhang, Jie Li, Rui Huang, Chao Wu
Summary: The coexistence of HBsAg and anti-HBs is associated with severe liver fibrosis and cirrhosis in patients with chronic hepatitis B, especially among those who are HBeAg negative.
